Traws Pharma
TRAW
34 hedge funds and large institutions have $5.19M invested in Traws Pharma in 2026 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 7 closing their positions.
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
21% more funds holding
Funds holding: 28 → 34 (+6)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
4.67% less ownership
Funds ownership: 45.3% → 40.63% (-4.7%)
22% less capital invested
Capital invested by funds: $6.62M → $5.19M (-$1.43M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
+$1.08M |
| 2 |
O
OrbiMed
New York
|
+$824K |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$750K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$611K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$549K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
-$936K |
| 2 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$464K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$276K |
| 4 |
PWM
Palumbo Wealth Management
Great Neck,
New York
|
-$112K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$83.5K |
TRAW Hedge Fund Activity: Q2 2026 in Review
34 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q2 2026, worth a combined $5.19M — down 22% from $6.62M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TRAW positions and 7 closed out — a net gain of 6 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Ally Bridge Group, opening a new position worth an estimated $1.08M. The largest seller was Squadron Capital Management, exiting entirely with an estimated $936K sold.
- 34 institutional investors held Traws Pharma (TRAW) as of Q2 2026, up from 28 in Q1 2026.
- Funds reported $5.19M of Traws Pharma stock for Q2 2026, down 22% quarter-over-quarter.
- 13 funds opened new Traws Pharma positions in Q2 2026 and 7 closed out, a net change of +6 holders.
- The largest Traws Pharma buyer in Q2 2026 was Ally Bridge Group, an estimated $1.08M added.
- The largest Traws Pharma seller in Q2 2026 was Squadron Capital Management, an estimated $936K sold.
Based on aggregated 13F filings for Q2 2026.